G1 Therapeutics Financial Statements (GTHX)
|
|
|
|
Report date
|
|
|
24.02.2021 |
23.02.2022 |
01.03.2023 |
14.04.2023 |
28.02.2024 |
|
08.08.2024 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
45.3 |
31.5 |
51.3 |
51.3 |
82.5 |
|
58.2 |
|
Operating Income, bln rub |
|
|
-96.5 |
-142.5 |
-136.2 |
-136.2 |
-39.5 |
|
-37.9 |
|
EBITDA, bln rub |
? |
|
-95.5 |
-142.5 |
-134.9 |
-134.9 |
-39.0 |
|
-35.4 |
|
Net profit, bln rub |
? |
|
-99.3 |
-148.4 |
-147.6 |
-147.6 |
-48.0 |
|
-44.8 |
|
|
OCF, bln rub |
? |
|
-83.7 |
-132.1 |
-128.6 |
-128.6 |
-38.3 |
|
-37.5 |
|
CAPEX, bln rub |
? |
|
0.000 |
0.000 |
0.506 |
0.506 |
0.000 |
|
0.000 |
|
FCF, bln rub |
? |
|
-83.7 |
-132.1 |
-129.1 |
-129.1 |
-38.3 |
|
-37.5 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
141.8 |
171.9 |
183.7 |
183.7 |
114.8 |
|
93.0 |
|
Cost of production, bln rub |
|
|
0.000 |
2.02 |
3.75 |
3.75 |
7.20 |
|
6.14 |
|
R&D, bln rub |
|
|
73.3 |
76.2 |
83.3 |
83.3 |
43.7 |
|
29.2 |
|
Interest expenses, bln rub |
|
|
1.78 |
4.67 |
10.4 |
10.4 |
10.0 |
|
8.94 |
|
|
Assets, bln rub |
|
|
228.6 |
254.1 |
188.0 |
188.0 |
121.5 |
|
98.7 |
|
Net Assets, bln rub |
? |
|
-436.1 |
-584.5 |
68.7 |
68.7 |
35.4 |
|
24.6 |
|
Debt, bln rub |
|
|
27.8 |
83.1 |
83.8 |
83.8 |
57.2 |
|
48.0 |
|
Cash, bln rub |
|
|
207.3 |
221.2 |
145.1 |
145.1 |
82.2 |
|
60.8 |
|
Net debt, bln rub |
|
|
-179.5 |
-138.1 |
-61.3 |
-61.3 |
-25.0 |
|
-12.8 |
|
|
Ordinary share price, rub |
|
|
18.0 |
10.2 |
5.43 |
5.43 |
3.05 |
|
1.61 |
|
Number of ordinary shares, mln |
|
|
37.9 |
41.9 |
43.6 |
43.6 |
51.7 |
|
52.5 |
|
|
Market cap, bln rub |
|
|
681 |
428 |
237 |
237 |
158 |
|
84 |
|
EV, bln rub |
? |
|
502 |
290 |
176 |
176 |
133 |
|
72 |
|
Book value, bln rub |
|
|
-436 |
-584 |
69 |
69 |
35 |
|
25 |
|
|
EPS, rub |
? |
|
-2.62 |
-3.54 |
-3.38 |
-3.38 |
-0.93 |
|
-0.85 |
|
FCF/share, rub |
|
|
-2.21 |
-3.15 |
-2.96 |
-2.96 |
-0.74 |
|
-0.72 |
|
BV/share, rub |
|
|
-11.5 |
-13.9 |
1.58 |
1.58 |
0.68 |
|
0.47 |
|
|
EBITDA margin, % |
? |
|
-210.9% |
-452.6% |
-263.0% |
-263.0% |
-47.3% |
|
-60.9% |
|
Net margin, % |
? |
|
-219.2% |
-471.3% |
-287.6% |
-287.6% |
-58.1% |
|
-76.9% |
|
FCF yield, % |
? |
|
-12.3% |
-30.8% |
-54.5% |
-54.5% |
-24.3% |
|
-44.4% |
|
ROE, % |
? |
|
22.8% |
25.4% |
-214.6% |
-214.6% |
-135.6% |
|
-182.1% |
|
ROA, % |
? |
|
-43.4% |
-58.4% |
-78.5% |
-78.5% |
-39.5% |
|
-45.4% |
|
|
P/E |
? |
|
-6.87 |
-2.89 |
-1.61 |
-1.61 |
-3.29 |
|
-1.89 |
|
P/FCF |
|
|
-8.14 |
-3.24 |
-1.83 |
-1.83 |
-4.12 |
|
-2.25 |
|
P/S |
? |
|
15.0 |
13.6 |
4.62 |
4.62 |
1.91 |
|
1.45 |
|
P/BV |
? |
|
-1.56 |
-0.73 |
3.45 |
3.45 |
4.46 |
|
3.44 |
|
EV/EBITDA |
? |
|
-5.26 |
-2.04 |
-1.30 |
-1.30 |
-3.40 |
|
-2.02 |
|
Debt/EBITDA |
|
|
1.88 |
0.97 |
0.45 |
0.45 |
0.64 |
|
0.36 |
|
|
R&D/CAPEX, % |
|
|
|
|
16 466% |
16 466% |
|
|
|
|
|
CAPEX/Revenue, % |
|
|
0.00% |
0.00% |
0.99% |
0.99% |
0.00% |
|
0 |
|
| G1 Therapeutics shareholders |
